Funding & Investment

AIM Youth Mental Health is a US non-profit foundation founded in 2014 that funds scientific research and youth-led participatory action research to improve mental health outcomes for young people. The organization funds psilocybin research—including a study on how psilocybin affects genetic aging markers in young adults with stress-related disorders—alongside fellowships for postdoctoral youth mental health innovators.

Able Partners is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Aja Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The Alexander Mosley Charitable Trust is a UK philanthropic foundation established in 2011 by Max Mosley in memory of his son, providing proactive grant-making to mental health and psychedelic research causes. The Trust is a principal funder of Imperial College London's Centre for Psychedelic Research, donating over £600,000 to support landmark psilocybin studies published in the New England Journal of Medicine and Nature Medicine.

Ambria Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The American Foundation for Suicide Prevention (AFSP) is the largest non-profit funder of suicide prevention research in the United States, supporting scientific research, survivor outreach, education programs, and advocacy to reduce loss of life from suicide. AFSP has cited emerging psychedelic research—including psilocybin and ketamine studies—among promising avenues for reducing suicidal ideation, reflecting the growing overlap between suicide prevention and psychedelic-assisted therapy.

The Anne and Don Fizer Foundation is a Houston, Texas-based private charitable foundation established in memory of estate planning attorney Don E. Fizer (1942–2011) and his wife Anne, supporting philanthropy in healthcare and medical research. The foundation has contributed to psychedelic research initiatives, participating in the growing wave of private philanthropic funding for clinical studies of psychedelic-assisted therapy in the United States.

Family office and investment group with repeated financing participation in psychedelic drug-development companies, including atai Life Sciences.

The Arizona Biomedical Research Commission (ABRC) is a state government body within the Arizona Department of Health Services that funds biomedical research, having become the first state agency in the US to direct $5 million toward randomized controlled clinical trials of psilocybin whole mushrooms for conditions including PTSD, depression, and addiction. The ABRC oversees the Arizona Psilocybin Research Advisory Council and has since expanded its psychedelic research portfolio to include an additional $5 million for ibogaine clinical trials.

Ark Invest is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Clinical-stage psychedelic company that also functions as a strategic-corporate capital allocator through legacy atai platform investments and deal activity in the sector.

BTIG is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

BVF Partners is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Longstanding non-profit foundation supporting and convening psychedelic and drug-policy research programs.

Fundación Beckley Med is a Barcelona-based psychedelic research and education organisation, partnered with the UK's Beckley Foundation, that funds and disseminates psychedelic-assisted therapy studies and provides professional training through institutional affiliations with MAPS, Grof Legacy, and CIIS. It collaborated with CITA Clinic to deliver experimental ketamine treatment to patients with treatment-resistant depression in Spain.

Beijing Medical Award Foundation (北京医学奖励基金会) is a Beijing-based public charity established in 2002 in Xicheng District, dedicated to enhancing medical standards through professional incentives, grants, and awards recognising biomedical research achievement. The foundation provides funding and recognition supporting clinical and scientific excellence in Chinese medicine, including psychiatry and neuroscience fields.

Berenberg is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Bicycle Day Ventures is tracked as a syndicate/network investor that may channel capital into psychedelic and adjacent mental-health ventures.

BlackRock is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Blackhawk Growth Corp is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Entrepreneur and donor listed in psychedelic philanthropy ecosystems with public wellbeing-focused giving activity.

Boxer Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The Brain & Behavior Research Foundation (formerly NARSAD) is the world's largest private funder of psychiatric research, having awarded over $475 million to more than 5,000 scientists—including grants specifically supporting psilocybin-assisted therapy trials, ketamine research, and other innovative treatments for depression, PTSD, and schizophrenia. In 2023 alone, the foundation funded seven grants advancing psilocybin-based research and has supported over 90 ketamine-related projects, making it a cornerstone funder of emerging psychedelic science.

Canada-based foundation backing translational and clinical research programs in mental health, including psychedelic-relevant workstreams.

The Bronx Veterans Medical Research Foundation (BVMRF) is a 501(c)(3) nonprofit that administers extramural research funding for the James J. Peters VA Medical Center and VA Hudson Valley Health Care System, supporting mental health, biomedical, and rehabilitation research focused on veteran populations. In the psychedelic context, it provides the administrative research infrastructure supporting MDMA-assisted therapy for PTSD and ketamine studies conducted at the Bronx VA's Center for Psychedelic Psychotherapy and Trauma Research.

The Burroughs Wellcome Fund (BWF) is an American biomedical research foundation headquartered in Research Triangle Park, North Carolina, that grants over $40 million annually to support early-career scientists and fields poised for significant advancement but currently undervalued—a mandate that encompasses avant-garde psychiatric pharmacology. The Fund traces its origins to Burroughs Wellcome Co., the US pharmaceutical subsidiary whose pioneering monoaminergic pharmacology research laid groundwork foundational to today’s psychedelic medicine field.

Canaccord Genuity is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Canadian federal health research funder with direct psilocybin psychotherapy trial grants.

Canada�s federal health research funding agency setting national biomedical and health-services research priorities.

Cantor Fitzgerald is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Psychedelic ecosystem founder and donor/investor associated with mission-aligned philanthropic support activity.

The Carey and Claudia Turnbull Family Foundation is a private philanthropic foundation that has been one of the earliest and most influential funders of psychedelic medicine research, supporting psilocybin studies at NYU, Yale, and Johns Hopkins—including helping establish Yale’s psychedelic psychiatry training curriculum and endowing research at the NYU Center for Psychedelic Medicine, where Carey Turnbull chairs the advisory board. Carey Turnbull also serves as President of the Heffter Research Institute and co-founded B.More and Ceruvia Lifesciences, further extending the family’s commitment to advancing psychedelic therapies for depression, addiction, and OCD.

Catalio Capital Management is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The Chief Scientist Office (CSO) of the Scottish Government funds NHS and health research across Scotland, and has supported University of Edinburgh evaluability work on ketamine-assisted therapy and the development of the Scottish Psychedelic Research Group to build Scotland’s capacity for psychedelic-assisted therapy studies.

Individual philanthropic donor listed in ecosystem mappings with limited publicly structured recipient-level disclosures.

U.S. federally directed defense-health research program office administering targeted grants, including mental-health priorities.

Brazil's National Council for Scientific and Technological Development (CNPq) is the country's primary public funding agency for scientific research, providing grants, scholarships, and R&D support to universities and research institutions nationwide. CNPq ranks among the top global funders of psychedelic science, having supported seminal ayahuasca clinical trials, pharmacological studies, and productivity fellowships for researchers who established Brazil as a world leader in psychedelic psychiatry.

CAPES (Coordenação de Aperfeiçoamento de Pessoal de Nível Superior) is Brazil's federal agency for graduate education improvement, providing scholarships, postdoctoral fellowships, and institutional research grants to universities nationwide. Ranked among the top-six global funders of psychedelic research in a 2023 Scopus analysis, CAPES has financed ayahuasca neuroscience studies, clinical investigations, and postdoctoral programmes that underpin Brazil's internationally recognised psychedelic research ecosystem.

The Council on Spiritual Practices (CSP) is a US non-profit organisation founded in 1993 by Robert Jesse to support research and education on the safe and effective use of entheogens and primary religious experience. CSP was instrumental in initiating the landmark Johns Hopkins psilocybin research programme with Roland Griffiths, co-funding pivotal early studies on psilocybin's mystical-experience effects that re-established psychedelic science and shaped clinical frameworks globally.

The Council on Spiritual Practices Fund at the San Francisco Foundation is a named charitable fund administered through the San Francisco Foundation, a regional community foundation serving the Bay Area. It channels philanthropic resources in support of research and education on entheogenic substances and primary religious experience, extending the grant-making mission of the Council on Spiritual Practices through a community foundation structure.

Cowen is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

The Czech Health Research Council (AZV ČR) is an organisational component of the Czech Ministry of Health responsible for funding applied health research, distributing over 1 billion CZK annually across approximately 90 supported projects per year. It provided the primary grant for the PSIKET001 trial — a landmark double-blind comparison of psilocybin versus ketamine for treatment-resistant depression at the National Institute of Mental Health — with a total budget of 12 million CZK.

Executive and donor with publicly documented support for psychedelic policy and research-aligned initiatives.

Deerfield is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

US defense research funder with psychedelic-informed neuropsychiatric R&D (Focused Pharma).

Mission-driven company with publicly documented donations and advocacy support for psychedelic research and policy reform initiatives.

EF Hutton is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Empath Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Empower Psychedelics is a Canada-based non-profit conducting Health Canada-approved psychedelic-assisted group therapy research for first responders and military veterans in partnership with MAPS Canada. Founded in 2020 by former first responders, the organization received a $205K Mitacs grant with the University of Quebec in Montreal for a two-year clinical research program.

Empower Research Inc. is the corporate research entity behind Empower Psychedelics, running Health Canada-approved trials on psychedelic-assisted group therapy for first responders in partnership with MAPS Canada. The organization has also studied medically perceived benefits of psychedelics and cannabinoids among first responders and military personnel.

The Etheridge Foundation is a 501(c)(3) non-profit founded by Grammy and Academy Award-winning musician Melissa Etheridge following the 2020 opioid overdose death of her son Beckett, funding scientific research into plant-medicine treatments for opioid use disorder and related mental health conditions. The Foundation has co-funded Usona Institute's 5-MeO-DMT research program and raised over $1 million at its inaugural Rock Jam gala for psychedelic medicine development.

EU supranational research funding framework supporting psilocybin clinical research (PsyPal).

Evercore is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Philanthropic foundation connected to Evolve Ventures focused on funding mental-health and psychedelic research initiatives.

Evolve Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The Fetzer Institute is a private non-profit foundation based in Kalamazoo, Michigan with $830M in assets, dedicated to building the spiritual foundation for a loving world through research at the intersection of science, spirituality, and consciousness. With annual grants exceeding $12M, the Institute supports interdisciplinary work in consciousness studies and contemplative practice that intersects with the emerging field of psychedelic medicine.

The Foundation of Hope for Research and Treatment of Mental Illness is a North Carolina non-profit that partners with UNC Chapel Hill's Department of Psychiatry to fund cutting-edge psychiatric research, with a mission to conquer mental illness through scientific investment. The Foundation's seed grants support a portfolio of mental health research at UNC Chapel Hill that includes ketamine and emerging psychedelic-assisted therapy studies alongside broader mental health initiatives.

The Michael J. Fox Foundation for Parkinson's Research (MJFF) is a New York-based non-profit founded in 2000 by actor Michael J. Fox that has raised over $2 billion for Parkinson's disease research and treatments. MJFF has funded pioneering psychedelic research including the first psilocybin trial in a neurodegenerative disease (UCSF/Yale, for Parkinson's-related depression) and a ketamine infusion trial at Yale for treatment-resistant depression in Parkinson's patients.

Future Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Grantmaking and philanthropic platform supporting nonprofits in consciousness, wellbeing, and psychedelic-adjacent ecosystems.

Gaingels is tracked as a syndicate/network investor that may channel capital into psychedelic and adjacent mental-health ventures.

Gateway for Cancer Research is a US non-profit that funds innovative cancer research including exploration of psychedelic-assisted therapies for cancer-related psychological distress and end-of-life care. The organization has actively promoted and publicized expert calls for expanded study of psilocybin and other psychedelics to address the anxiety, depression, and existential distress experienced by cancer patients.

The George Sarlo Foundation is the philanthropic vehicle of Holocaust survivor and Silicon Valley venture capitalist George Sarlo, who credits guided psychedelic experiences with resolving his childhood trauma and became one of the earliest major private donors to psychedelic science. The Foundation has contributed nearly $2 million to psychedelic research, including a $1 million pledge to MAPS for MDMA-assisted therapy development and grants to CIIS for psychedelic therapist diversity training.

The German Federal Ministry of Education and Research (BMBF) is the pioneering Western government funder of large-scale psychedelic clinical trials, having provided approximately €5 million to the EPIsoDE study — the first government-funded Phase 2 psilocybin trial for treatment-resistant major depression — conducted at the Central Institute for Mental Health in Mannheim and Charité Berlin. Germany subsequently became the first EU country to establish a psilocybin compassionate access program for treatment-resistant depression.

The Antonio J. Gracias Family Foundation is a Chicago-based private philanthropic foundation established in 2021 that awarded a $16 million gift to Harvard University to fund interdisciplinary psychedelic research, including the Project on Psychedelics Law and Regulation (POPLAR) at Harvard Law School and the Transcendence and Transformation Initiative at the Center for the Study of World Religions. With $94.6 million in assets, the foundation identifies psychedelics as a priority research area alongside quantum science and cardiovascular medicine.

H.C. Wainwright & Co. is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

The Hartford HealthCare (HHC) Research Open Competition is an internal pilot grant program run by Hartford HealthCare — a large non-profit integrated health system in Connecticut — to fund investigator-initiated research at its affiliated institutions. Through this program, HHC supports a Phase I double-blind psilocybin microdosing trial at its Olin Neuropsychiatry Research Center in Hartford, investigating effects on cognition, mood and quality of life.

Healing Hearts, Changing Minds, Inc. (HHCM) is a Massachusetts-based nonprofit grant foundation committed to trust-based philanthropy in psychedelic-assisted therapy, founded by Robert Ansin following a transformative personal psilocybin experience. The foundation has awarded over $566,000 in grants under its 'Walking Each Other Home' fund to support psilocybin and ketamine-assisted therapy in end-of-life care, including funding for war-affected Ukrainian veterans.

The Health Research Board (HRB) is Ireland's primary statutory health research funding agency, which has awarded grants to Trinity College Dublin's Psychedelic Research Group to investigate psychedelics' immune effects in depression and the feasibility of psilocybin for cocaine-use disorder. The HRB also funds the KARMA-DEP(2) ketamine trial for treatment-resistant depression at St Patrick's University Hospital in Dublin, making it a key enabler of Ireland's emerging psychedelic medicine ecosystem.

Non-profit organization funding and coordinating research on classic psychedelics and related therapies.

The Henry M. Jackson Foundation for the Advancement of Military Medicine (HJF) is a congressionally chartered non-profit founded in 1983 that manages research contracts and grants for the U.S. Department of Defense across global health, HIV, TBI, and PTSD. HJF is affiliated with clinical research investigating ketamine for sedation in severe traumatic brain injury — a condition at the intersection of military medicine and emerging ketamine-based therapies.

Hercules Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Platform organization developing and supporting psychedelic and mental-health initiatives with philanthropic backing.

French National Institute of Health and Medical Research (INSERM), a national public biomedical research organization with active discourse and research engagement on psychedelic medicine.

Institut National de la Santé et de la Recherche Médicale (INSERM) is France's national public health and medical research agency, funding and conducting biomedical research across university-hospital institutes throughout the country. INSERM-affiliated researchers at the Paris Brain Institute (ICM) and Pitié-Salpêtrière Hospital have contributed to preclinical and clinical investigations of ketamine and psilocybin as rapid-acting antidepressants.

Instituto de Salud Carlos III (ISCIII) is Spain's national public health research agency, managing the CIBERSAM network (Centro de Investigación Biomédica en Red de Salud Mental) which co-funds biomedical mental health research across Spanish universities and hospitals. Through CIBERSAM, ISCIII has co-funded preclinical and translational research on psilocybin as an antidepressant and supports researchers contributing to the European psychedelic therapy landscape.

ICEERS (International Center for Ethnobotanical Education, Research and Service) is a nonprofit supporting ethnobotanical research, policy engagement, and community-informed programming around ayahuasca, iboga, and related plant medicines.

Psychedelic-focused venture capital firm investing in drug development, care delivery, and platform infrastructure across the sector.

JLS Fund is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The James S. McDonnell Foundation is a private philanthropic organization based in St. Louis, Missouri, supporting research in cognitive and behavioral sciences, complex systems science, and 21st-century science education. The foundation has funded clinical research on cognitive recovery following electroconvulsive therapy and general anesthesia.

Jefferies is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Johnson & Johnson is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Reciprocity trust linked to Journey Colab focused on equitable benefit sharing and funding commitments around psychedelic medicine development.

Entrepreneur included in psychedelic philanthropy ecosystem lists; available public disclosures are currently limited.

The Juvenile Bipolar Research Foundation is a US non-profit dedicated to funding scientific research into bipolar disorder in children and adolescents. The foundation has supported clinical research on intranasal ketamine for pediatric bipolar disorder and neurobiological studies of ketamine's effects in children and adults with bipolar disorder.

Kevin O'Leary is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Leafy Tunnel is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Levitee Labs is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

MBX Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Matt Mullenweg is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Maxim Group is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

The Medical Research Council (MRC) is a UK government body under UKRI that funds biomedical and clinical research across all aspects of human health. In the psychedelic field, the MRC co-funded the KARE trial — the UK's largest study of ketamine-assisted therapy for alcohol use disorder, led by the University of Exeter — and has supported additional ketamine cognition research.

Australian Government medical research funder with explicit psychedelic trial grants (including ketamine, psilocybin, and MDMA).

Mike Novogratz is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Mission Club is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Mitacs is a Canadian nonprofit research organization founded in 1999 that fosters collaboration between academia, industry, and government through internship, fellowship, and innovation programs jointly funded by federal and provincial partners. In the psychedelic field, Mitacs provided an Accelerate grant (IT32313) to Empower Psychedelics for a Health Canada-approved clinical trial examining psilocybin-assisted group therapy for first responders and veterans in partnership with MAPS Canada.

Morgan Stanley is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

The National Alliance for Research on Schizophrenia and Depression (NARSAD), now the Brain & Behavior Research Foundation (BBRF), is the United States’ largest non-governmental funder of mental health research, having awarded over $430 million across 6,200+ grants to more than 5,100 scientists worldwide since 1987. NARSAD-funded Distinguished Investigator grants supported early research into ketamine’s antidepressant mechanism at Columbia University, as well as studies of salvinorin A pharmacology and ketamine augmentation of electroconvulsive therapy for depression.

NIH institute funding psychedelic oncology-adjacent mental health research, including psilocybin therapy studies for advanced cancer-related distress.

The National Cancer Institute (NCI) is the principal US federal agency for cancer research and training, one of 27 institutes within the National Institutes of Health, with an annual budget exceeding $7 billion. In the psychedelic field, NCI has supported trials exploring psilocybin-assisted therapy for cancer-related demoralization and chronic pain in survivors, as well as ketamine infusion to prevent depression in patients undergoing treatment for pancreatic and head-and-neck cancers.

NIH center that accelerates the translation of biomedical discoveries into health solutions. NCATS' Clinical and Translational Science Awards (CTSA) program funds the infrastructure at academic medical centers that supports emerging research including psychedelic-assisted therapy trials.

NIH institute funding psychedelic clinical research, including psilocybin-assisted psychotherapy protocols in depression and chronic pain populations.

U.S. federal institute focused on complementary/integrative research and evidence programs including psychedelic-adjacent contexts.

The National Center for Research Resources (NCRR) was a National Institutes of Health centre that funded biomedical research infrastructure, clinical and translational science programmes, and shared research resources until its dissolution in 2011, when its programmes were reorganised primarily into the new National Center for Advancing Translational Sciences (NCATS). NCRR infrastructure and clinical research awards supported early NIH-funded investigations into glutamate-modulating medications for major depressive disorder that laid the mechanistic groundwork for understanding ketamine’s rapid antidepressant effects.

The National Council of Scientific and Technical Research (CONICET; Consejo Nacional de Investigaciones Científicas y Técnicas) is Argentina’s principal government agency for promoting science and technology, funding over 11,000 researchers and 10,000 doctoral students across a nationwide network of research institutes and centres. CONICET supported the NATMICRO study, a naturalistic observational investigation of the psychological and cognitive effects of self-administered psilocybin microdosing conducted in Argentina.

The National Health and Medical Research Council is the Australian Government body for health and medical research funding, evidence guidance, and research ethics. It is tracked here as a public funder for Australian clinical research.

UK public health research funder and implementation infrastructure supporting NHS-oriented evidence generation.

UK public health research funder with NIHR-backed psilocybin addiction trial funding.

U.S. federal institute defining mental-health research agendas and evidence-generation priorities including psychedelic-relevant studies.

NIH institute funding neuroscience projects involving psychedelics, including psilocybin-related chronic pain and neuroplasticity investigations.

NIH institute with co-funded psychedelic research activity, including projects on psychedelics for older adults with chronic pain.

NIH institute funding psychedelic-related alcohol use disorder research, including psilocybin-assisted treatment and derivative development projects.

The National Institute on Alcohol Abuse and Alcoholism (NIAAA) is a US National Institutes of Health institute dedicated to research on alcohol use disorder and its public health impacts, supporting approximately $500 million in research annually. NIAAA has funded studies exploring both ketamine administration for acute alcohol use disorder in the emergency department and psilocybin-assisted therapy to understand the neurobehavioral mechanisms underlying alcohol use disorder treatment.

U.S. federal institute setting addiction-research priorities and portfolios, including psychedelic-related investigations.

U.S. federal biomedical research agency shaping institute-level priority and research funding architecture.

Negev Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Neo Kuma is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Private foundation with explicit support for psychedelic research, science communication, and ecosystem development.

Impact-oriented investment fund focused on psychedelic medicine and consciousness-related innovation with explicit sector-specific framing.

Philanthropic initiative focused on funding and scaling mental-health innovation, including psychedelic-related ecosystem efforts.

The Novo Nordisk Foundation is a Danish enterprise foundation that funds scientific, health, and societal research. In this dataset it is tracked as a funding stakeholder for clinical research rather than as a trial sponsor operating company.

OMX Venture is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Dutch nonprofit organizer in the psychedelic field, including stewardship of the ICPR conference series and related professional convenings.

Oppenheimer is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

The Oppenheimer Family Psychosocial Oncology and Palliative Care Research Grants is a philanthropic grant fund supporting research at Dana-Farber Cancer Institute's Department of Psychosocial Oncology and Palliative Care, including Dr. Yvan Beaussant's psilocybin-assisted therapy studies for demoralization and existential distress in hospice patients. The program co-funds trials alongside the Heffter Research Institute, Usona Institute, and Nikean Foundation.

Orbimed Advisors is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Origin Therapeutics is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Oscillate is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Foundation funding psychedelic and mental-health innovation programs, linked to HumanKindLabs initiatives.

Otsuka is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Venture capital fund focused on psychedelic and broader mental health innovation, with portfolio activity across therapeutics and enabling infrastructure.

Pancreatic Cancer North America is an IRS-registered 501(c)(3) non-profit dedicated to fighting the world's toughest cancer through research funding, patient support, and awareness initiatives, which has funded a psilocybin-assisted therapy study at Dana-Farber Cancer Institute examining psilocybin's potential to relieve opioid-refractory pain and psychological distress in patients with advanced pancreatic cancer.

The Patient-Centered Outcomes Research Institute (PCORI) is a Washington, DC–based independent non-profit (501(c)(1)) created by the 2010 Affordable Care Act to fund comparative effectiveness research. PCORI awarded $12.6 million to Yale University researchers to directly compare IV racemic ketamine versus intranasal esketamine (Spravato) for treatment-resistant depression, and separately funded the ELEKT-D ketamine vs. ECT effectiveness trial conducted through the Cleveland Clinic Foundation.

Angel investor and entrepreneur with publicly documented participation in atai Life Sciences financing rounds tied to psychedelic drug-development.

Phyto Partners is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Presight Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Prime Movers Lab is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Private Philanthropic Funds is a ClinicalTrials.gov funder category representing anonymous private philanthropic donors, appearing as a collaborator on Johns Hopkins University research including the Phase 1 safety study for at-home administration of microdose psilocybin (NCT06450210). The Psychedelic Science Funders Collaborative (psfc.co) is the leading coordinating body for such private philanthropists dedicated to advancing psychedelic therapy research.

Venture investment platform focused on psychedelic and mental health innovation with emphasis on clinically actionable models.

Psych Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Collaborative funding network coordinating philanthropy and grant strategy for psychedelic science initiatives.

Pura Vida Investments is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

QC Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

RA Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

RTW Venture Fund is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The Rett Syndrome Research Trust (RSRT) is a US-based nonprofit dedicated to curing Rett syndrome (RTT) that funded, held the IND for, and oversaw a randomized double-blind placebo-controlled crossover trial of oral ketamine in girls aged 6-12 with RTT; the study confirmed safety and tolerability and demonstrated EEG evidence of NMDA receptor target engagement, supporting further trials with longer duration or higher doses.

Foundation funding psychedelic science, policy, and education initiatives across the emerging ecosystem.

Roth Capital is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Route 66 Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The Royal University Hospital Foundation is the charitable fundraising arm of Royal University Hospital in Saskatoon, Saskatchewan, which has invested over $194 million into research, education, and patient care at Saskatchewan's largest academic hospital; the Foundation has supported psychiatry research including ECT and ketamine anesthesia comparative trials and Dr. Evyn Peters' groundbreaking work using intranasal racemic ketamine for hospitalized patients with treatment-resistant depression.

The Quebec Network on Suicide, Mood Disorders and Associated Disorders (RQSHA) is a publicly-funded interdisciplinary research network supported by the Fonds de recherche du Québec that brings together researchers from across Quebec to study suicide, mood disorders, and substance use; it has funded several ketamine trials including the 'Montreal Model' study integrating psychedelic-informed ketamine therapy with psychological support for severe treatment-resistant depression, and research on music as an intervention to improve ketamine tolerability in depression treatment.

The Schulman Research Award is a Canadian research award that has provided funding for clinical anesthesia and psychiatry research; in the psychedelic-adjacent field, it supported a randomized study at the University of Saskatchewan comparing ketamine-based versus propofol-based anesthesia for electroconvulsive therapy (ECT) in patients with treatment-resistant major depressive disorder, which found that ketamine-based anesthesia resulted in superior treatment outcomes on the Montgomery-Åsberg Depression Rating Scale.

The Swiss National Science Foundation (Schweizerischer Nationalfonds, SNF) is Switzerland's principal public funder of scientific research across all academic disciplines; in the psychedelic field, it has funded multiple clinical trials including psilocybin studies for alcohol use disorder and major depressive disorder, contributing to Switzerland's position as the world's second-largest hub for psychedelic clinical research with over 35 trials and a historic connection to Albert Hofmann's discovery of LSD and isolation of psilocybin at Basel.

The Special Operations Care Fund (SOC-F) is a US non-profit organization based in Atlanta, Georgia, that provides direct support to active and retired members of the Special Operations Forces community and their families. It is the sponsor of the Trifecta Research Study — conducted with Johns Hopkins Center for Psychedelic and Consciousness Research — which investigates hormone replacement therapy, magnetic e-resonance therapy (MeRT), ibogaine, and 5-MeO-DMT in combination for the treatment of PTSD and TBI-related cognitive impairment in SOF veterans.

Private foundation with publicly documented support for psychedelic and mental-health research initiatives.

Stifel is tracked as an institutional-capital stakeholder relevant to financing exposure in psychedelic and adjacent mental-health sectors.

Subversive Capital is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Tabula Rasa Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The state public health agency for Texas, responsible for promoting and protecting the health of Texans through disease prevention, health promotion, and oversight of public health services. The agency licenses healthcare facilities, monitors communicable diseases, and supports mental health and substance use programs.

Texas state health agency overseeing policy functions and implementation of psychedelic-adjacent public initiatives such as ibogaine programs.

The philanthropic vehicle of the Council on Spiritual Practices (CSP), administered as Fund #4745 within the San Francisco Foundation. CSP is a nonprofit organization that played a foundational role in supporting psilocybin research at Johns Hopkins University, including landmark studies on mystical experience, spiritual practice, and the therapeutic potential of psychedelics.

The Conscious Fund is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Czech philanthropic foundation supporting research and public education initiatives related to psychedelics.

Named fellowship program supporting journalism capacity around psychedelic science and policy.

A nonprofit organization based in San Anselmo, California, dedicated to advancing the therapeutic use of ketamine and psychedelic medicines. Founded by Dr. Phil Wolfson, the Ketamine Research Foundation conducts FDA-approved clinical research on ketamine-assisted psychotherapy, operates the premier Ketamine Training Center, and maintains a comprehensive scholarly library on ketamine therapeutics.

Named endowed-funding initiative supporting sustained psychedelic science leadership at Johns Hopkins.

The Wallace Foundation is a US national philanthropy that funds research and practice in education, arts, and youth development. The foundation supports programs that expand learning opportunities for disadvantaged young people and strengthen cultural organizations. Its presence in clinical research records may reflect its growing interest in youth mental health and social-emotional learning initiatives.

Entrepreneur and donor included in psychedelic-focused philanthropy mappings; public recipient-level detail is currently limited.

Tim Ferriss is tracked as an angel-capital stakeholder based on inclusion in the legacy psychedelic investor mapping list.

Foundation supporting mental-health and psychedelic-adjacent initiatives with explicit wellbeing and societal impact framing.

UK-based policy foundation supporting evidence-driven drug policy reform, including psychedelic policy pathways.

U.S. Army medical R&D command supporting military biomedical research and administration pathways connected to DoD psychedelic clinical trial funding.

U.S. federal veterans health authority with explicit psychedelic-adjacent clinical research and care-implementation activity through VA research and care networks.

Federal defense department overseeing military health R&D and psychedelic-related clinical trial funding via DHA/DMRDP implementation.

Naval Medical Center San Diego (NMCSD) is the US Navy’s largest hospital on the West Coast, providing medical care to active-duty military personnel, retirees, and their families. Its Department of Psychiatry participates in clinical trials investigating MDMA-assisted and psilocybin-assisted therapies for PTSD and depression in service members, contributing to the DoD’s expanding psychedelic research program.

The VA Connecticut Healthcare System provides comprehensive medical and mental health services to veterans across Connecticut, with campuses in West Haven and Newington. As part of the VA's expanding psychedelic research program, it participates in clinical trials investigating MDMA-assisted therapy and psilocybin for PTSD and related conditions affecting veterans.

U.S. Veterans Affairs research authority overseeing national veteran-focused clinical research programs including psychedelic-adjacent initiatives.

The VA Puget Sound Health Care System serves veterans across the Pacific Northwest with major facilities in Seattle and Tacoma, Washington. As part of the VA’s expanding psychedelic research program, it participates in clinical trials examining MDMA-assisted therapy and psilocybin for PTSD and depression in veterans.

A nonprofit philanthropic organization dedicated to supporting Vail Health and its affiliated behavioral health programs in Eagle County, Colorado. The Vail Health Foundation generates philanthropy for Shaw Cancer Center, Eagle Valley Behavioral Health, and allied community nonprofits, with a $100 million campaign focused on transforming behavioral health care across mountain communities.

Vancouver Island Health Authority (Island Health) is a publicly funded regional health authority serving Vancouver Island and surrounding communities in British Columbia, Canada. Island Health operates hospitals, mental health services, and community health programs for over 800,000 residents, and supports clinical research including innovative approaches to psychedelic-assisted mental health treatment.

Västra Götalandsregionen (Region Västra Götaland) is the regional government and public health authority for western Sweden, including the Gothenburg metropolitan area and surrounding counties. With 1.7 million residents served by 17 hospitals and over 50,000 employees, it is one of Sweden's largest public employers and a major supporter of clinical psychiatric research.

Venrock Healthcare Capital Partners is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Vine Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

Walter Reed National Military Medical Center (WRNMMC) is the United States' premier military medical center, located in Bethesda, Maryland and operated jointly by the Army and Navy. It provides advanced medical care to active duty service members, veterans, retirees, and their families, and conducts clinical research on PTSD, traumatic brain injury, and emerging treatments for military personnel.

What If Ventures is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

The World Health Organization (WHO) is the United Nations' specialized agency for international public health, founded in 1948 and headquartered in Geneva, Switzerland. WHO sets global health standards, coordinates disease surveillance, and provides technical guidance on mental health, substance use disorders, and the international scheduling of controlled substances including psychedelics.

Y Combinator is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.

ZonMw (The Netherlands Organisation for Health Research and Development) is a Dutch government organization that funds and steers health research and healthcare innovation on behalf of the Ministry of Health, Welfare and Sport and the Dutch Research Council (NWO). ZonMw finances studies across all healthcare domains including mental health, substance use disorders, and novel therapeutic approaches such as psychedelic-assisted therapy.

Corporate philanthropy initiative launched by atai to support equitable mental-health innovation and psychedelic ecosystem programs.

atai-funded fellowship program in psychedelic neuroscience supporting trainee and early-career researchers.

re.Mind is tracked as a venture-capital stakeholder in the legacy psychedelic investor mapping list and is included for ongoing evidence enrichment.